This company has been acquired
Sigilon Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Sigilon Therapeutics has a total shareholder equity of $27.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $55.6M and $28.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$34.90m |
| Equity | US$27.45m |
| Total liabilities | US$28.11m |
| Total assets | US$55.56m |
Recent financial health updates
Recent updates
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet
Apr 17
Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M
Aug 04Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer
Jun 14What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?
Mar 04Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.
Dec 17Financial Position Analysis
Short Term Liabilities: SGTX's short term assets ($44.9M) exceed its short term liabilities ($25.2M).
Long Term Liabilities: SGTX's short term assets ($44.9M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: SGTX is debt free.
Reducing Debt: SGTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SGTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.6% each year